Choose Your Country or Region

Ustekinumab (anti-IL-12/IL-23)

Synonyms: CNTO 1275

Catalog No.A2024 Purity:99.12%

Ustekinumab (CNTO 1275) is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody used to treat psoriasis. MW=145.6 kDa.

Click to purchase the isotype control of Ustekinumab (anti-IL-12/IL-23)

Purity & Quality Control

Batch: A202401 Purity: 99.12% Protein concentration: 5.00mg/ml Endotoxin Level: ≤1 EU/mg

99.12

Choose Selective Interleukins Inhibitors

Expand to Check More

1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Biological Activity

Description	Ustekinumab (CNTO 1275) is an anti-IL-12/IL-23 IgG1κ human monoclonal antibody used to treat psoriasis. MW=145.6 kDa.

In Vitro
In vitro	The addition of Ustekinumab (UST) significantly inhibits T follicular helper (TFH) cell differentiation in vitro.^[1]
Cell Research:	Objective: TFH cell differentiation assay Cells: naïve CD4+ T cells, T follicular helper (TFH) cells, PBMCs Concentrations: 100 ng/mL Incubation Time: 24 h Method: The TFH cell differentiation assay is performed with freshly isolated PBMCs from healthy donors (n = 16). Naïve CD4+ T cells are isolated by using the human Naïve CD4+ T Cell Isolation Kit II. A total of 500,000 naïve CD4+ T cells are cultured in complete medium in the presence of 12.5 μL/mL anti-CD3/CD28 in a flat-bottom 48 well plate. After 24 hours of culture, cytokines are added and cells are incubated for additional 2.5 days. A total of 5 ng/mL IL-12 + 5 ng/mL TGFβ with and without 100 ng/mL UST and 100 ng/mL UST alone are used. Reference: https://pubmed.ncbi.nlm.nih.gov/32679193 Ustekinumab can apply to humanized mice, peripheral blood and other related assays (Only for Reference)

In Vitro

In vitro

The addition of Ustekinumab (UST) significantly inhibits T follicular helper (TFH) cell differentiation in vitro.^[1]

Cell Research:

Objective: TFH cell differentiation assay
Cells: naïve CD4+ T cells, T follicular helper (TFH) cells, PBMCs
Concentrations: 100 ng/mL
Incubation Time: 24 h
Method: The TFH cell differentiation assay is performed with freshly isolated PBMCs from healthy donors (n = 16). Naïve CD4+ T cells are isolated by using the human Naïve CD4+ T Cell Isolation Kit II. A total of 500,000 naïve CD4+ T cells are cultured in complete medium in the presence of 12.5 μL/mL anti-CD3/CD28 in a flat-bottom 48 well plate. After 24 hours of culture, cytokines are added and cells are incubated for additional 2.5 days. A total of 5 ng/mL IL-12 + 5 ng/mL TGFβ with and without 100 ng/mL UST and 100 ng/mL UST alone are used.
Reference: https://pubmed.ncbi.nlm.nih.gov/32679193

Ustekinumab can apply to humanized mice, peripheral blood and other related assays (Only for Reference)

In Vivo
In vivo	Ustekinumab is generated via recombinant human IL-12 immunization of human Ig (hu-Ig) transgenic mice. Ustekinumab binds to the p40 subunit common to IL-12 and IL-23 and prevents their interaction with the IL-12 receptor β1 subunit of the IL-12 and IL-23 receptor complexes.^[2]

References
[1] Anna-Maria Globig, et al. Cell Mol Gastroenterol Hepatol. 2021;11(1):1-12. [2] Jacqueline M Benson, et al. MAbs. Nov-Dec 2011;3(6):535-45.

References

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID

Product Details

CAS No.	815610-63-0
Isotype	Human IgG1
Source	Human
Formulation	PBS, PH7.2
Storage (From the date of receipt)	Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

^*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Tech Support

If you have any other enquiries, please leave a message.

* Indicates a Required Field

* Name Please enter your name.

* Email Please enter your email. Please enter a valid email address.

Phone

* Comments: Please write something to us.